Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Human LPA Protein, N-His

Catalog #:   YHC33401 Specific References (50) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: P08519
Protein length: Asp1719-Arg2038
Overview

Catalog No.

YHC33401

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Asp1719-Arg2038

Predicted molecular weight

35.41 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

P08519

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

Apolipoprotein(a), LPA, Lp(a), Apo(a)

Data Image
References

Lysophosphatidic acid and sphingosine-1-phosphate are apical polarity cues in multiple organoid systems., PMID:40503936

Lipoprotein(a) and its linear association with all-cause and cardiovascular mortality in patients with acute coronary syndrome., PMID:40496568

Tetramethylpyrazine enhances neuroprotection and plasticity in cerebral ischemia-reperfusion injury via RhoA/ROCK2 pathway inhibition., PMID:40495884

Lipoprotein(a) levels in Down syndrome: A conundrum., PMID:40474237

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial., PMID:40473449

Role of Lysophosphatidic Acid in Neurological Diseases: From Pathophysiology to Therapeutic Implications., PMID:40464500

KILDA: identifying KIV-2 repeats from kmers., PMID:40453649

Association of Blood Lipoprotein Levels With Incident Alzheimer Disease in Community-Dwelling Individuals: The Framingham Heart Study., PMID:40446198

Elevated lipoprotein(a) and its association with early-onset myocardial infarction and coronary burden., PMID:40445959

Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies., PMID:40436467

Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques: A PROSPECT II Substudy., PMID:40436465

Advancements in Biomarkers for Early Detection and Risk Stratification of Cardiovascular Diseases-A Literature Review., PMID:40432692

Lipoprotein(a) and Effects of Diet: Time for Reassessment., PMID:40431454

Biomarkers of Calcification, Endothelial Injury, and Platelet-Endothelial Interaction in Patients with Aortic Valve Stenosis., PMID:40430015

Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution., PMID:40420307

Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis: The Pooling Project., PMID:40417812

Lipoprotein(a) and panvascular disease., PMID:40413492

Association of Lipoprotein(a) With Major Adverse Limb Events and All-Cause Mortality Following Revascularization for Chronic Limb-Threatening Ischemia: A Substudy of the BEST-CLI Trial., PMID:40401600

Serum Lipoprotein(a) and High-Sensitivity C-reactive Protein Correlate With Somatic Parameters Including MLPA Subgroups in Children With Prader-Willi Syndrome., PMID:40401233

Physical Activity Modifies the Metabolic Profile of CD4+ and CD8+ T-Cell Subtypes at Rest and Upon Activation in Older Adults., PMID:40400170

Association of Lipoprotein(a) with cardiovascular events among individuals with autoimmune conditions., PMID:40398292

An evaluation of recaticimab for the treatment of hypercholesterolemia., PMID:40380894

Elevated plasma concentrations of lipoprotein (a) are associated with cardiovascular diseases in patients with early-onset type 2 diabetes mellitus., PMID:40370778

Engineering an alkaline-stable protein A through rational design strategies., PMID:40367905

LPAR6 Inhibits the Progression of Hepatocellular Carcinoma (HCC) by Suppressing the Nuclear Translocation of YAP/TAZ., PMID:40362442

Multiple LPA3 Receptor Agonist Binding Sites Evidenced Under Docking and Functional Studies., PMID:40362362

Physical Activity Assessment in Patients With Nephrotic Syndrome and the Impact of COVID-19: A Study Using the International Physical Activity Questionnaire and Accelerometry., PMID:40357065

Lysophosphatidic acid (LPA) receptor signaling modulates cellular functions of colon cancer cells under cobalt chloride-induced hypoxic conditions., PMID:40345063

Hepatic AKAP1 deficiency exacerbates diet-induced MASLD by enhancing GPAT1-mediated lysophosphatidic acid synthesis., PMID:40341440

The Brussels International Declaration on Lipoprotein(a) Testing and Management., PMID:40340180

Residual lipoprotein(a)-associated risk in patients with stroke or transient ischemic attack., PMID:40339358

Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease., PMID:40334781

Lipoprotein(a) and Its Association with Coronary Heart Disease: Data from a Large Cohort in the Russian., PMID:40331644

Lipoprotein(a) Concentration and Cardiovascular Disease in a Group of Patients With Familial Hypercholesterolemia-A Lipid Clinic Experience., PMID:40331566

Lipoprotein-a and white matter abnormalities: predicting small vessel disease in young patients with ischemic cerebrovascular events., PMID:40327115

LDL-cholesterol, lipoprotein(a) and high-sensitivity low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events., PMID:40320753

Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort., PMID:40318255

CRISPR/Cas9-mediated gene editing of MsCLE3a confers compact alfalfa architecture., PMID:40312015

Causal Relevance of Lp(a) for Coronary Heart Disease and Stroke Types in East Asian and European Ancestry Populations: A Mendelian Randomization Study., PMID:40297899

A novel lysophosphatidic acid receptor 1 antagonist with high brain penetrability has a curative effect in the empathic pain-related fibromyalgia model., PMID:40288824

Relationship Between Fermented Food Consumption Patterns, hs-CRP, and Chronic Diseases Among Middle-Aged Koreans: Data from the 2015-2018 Korea National Health and Nutrition Examination., PMID:40284207

Lipoprotein(a) and Risk of Incident Atherosclerotic Cardiovascular Disease: Impact of High-Sensitivity C-Reactive Protein and Risk Variability Among Human Clinical Subgroups., PMID:40284189

Gαq/11 Signaling Modulates Fibroblast Growth Factor 23 Production and Contributes to Acute Kidney Injury., PMID:40275688

Prevalence of Elevated Lipoprotein(a) and its Association With Subclinical Atherosclerosis in 2.9 Million Chinese Adults., PMID:40266173

Lp(a): A Clinical Review., PMID:40258460

Variants in candidate genes and their interactions with smoking on the risk of acute coronary syndrome., PMID:40257950

The effect of highly bioavailable forms of curcumin on lipoprotein(a) plasma levels: A systematic review and meta-analysis of randomized clinical studies., PMID:40252824

Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) Registry., PMID:40240882

BTX-A inhibited trigeminal neuralgia by blocking the NLRP3 pathway in rats., PMID:40220966

High-Density Lipoprotein Particles, Inflammation, and Coronary Heart Disease Risk., PMID:40218941

Datasheet
$ 330
Product specifications
100 μg 330 1 mg 1880

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human LPA Protein, N-His [YHC33401]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only